Re: Farmas USA
Dynavax Tech's lead candidate combined with Keytruda shows positive action in early-stage studies
Apr. 16, 2018 3:40 PM ET|About: Dynavax Technologies C... (DVAX)|By: Douglas W. House, SA News Editor
Dynavax Technologies' ( DVAX -6.8%) lead candidate SD-101, combined with Merck's ( MRK +2.6%) KEYTRUDA (pembrolizumab), showed positive effectsin early-stage studies in head-and-neck cancer and melanoma. The data are being presented at the American Association for Cancer Research Annual Meeting in Chicago.
Preliminary results from a Phase 1b/2 study in patients with advanced head-and-neck squamous cell carcinoma showed showed an objective response rate (ORR) of 33% (n=6/18) with no dose-limiting toxicities.
Preliminary data from a Phase 1b/2 study in advanced melanoma showed that 86% of the initial responses were sustained after a median of 18 months (n=6/7) in patients not previously treated with a PD-1 inhibitor. 17% (n=2/12) of evaluable patients who progressed on prior anti-PD-1 therapy achieved partial or stable disease for at least 10.5 months.
Median progression-free survival (PFS), duration of response and median overall survival (OS) have not been reached.
Previously: Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours (June 2, 2017)
-----
En 2017 dijeron que 100%, ahora que 86 % y que no se ha alcanzado la tasa media de supervivencia libre de progresion